THE CHALLENGE
Antibiotic-resistant infections kill 700,000 people annually – a number projected to reach 10 million by 2050 – yet pharmaceutical companies have largely abandoned antimicrobial development due to poor financial returns. AMR Action Fund was created to solve this market failure by investing in urgently needed therapeutics, but they faced a credibility gap: how do you convince the world’s top researchers and investors to trust a new fund tackling one of medicine’s most challenging problems?
THE SOLUTION
We positioned AMR Action Fund not as another investment vehicle, but as the catalyst that would reshape how society values lifesaving antimicrobials. Through sophisticated, science-first branding and messaging, we established their authority in the antimicrobial research community and built trust with the caliber of investors needed to fund breakthrough therapies. Our strategic approach communicated both the urgency of the antimicrobial resistance crisis and AMR’s unique ability to bridge the gap between scientific innovation and sustainable investment. The result: a brand presence that attracts world-class researchers, convinces institutional investors, and positions AMR as the definitive leader in antimicrobial development funding – turning their ambitious goal of launching 2–4 new antibiotics by 2030 from aspiration into inevitability.